Processa Pharmaceuticals Announces Launch of Website to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499.
ENPNewswire-August 5, 2022--Processa Pharmaceuticals Announces Launch of Website to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499
(C)2022 ENPublishing - http://www.enpublishing.co.uk
Release date- 04082022 - HANOVER, MD - Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), ('Processa' or the 'Company'), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical need conditions, announces that it has launched a new website Necrobiosislipoidicastudy.com. The website is designed to increase awareness of ulcerative Necrobiosis Lipoidica ('uNL'), an extremely rare condition, and to inform patients about the ongoing Phase 2 study that is investigating the use of PCS499 for the treatment of this rare condition.
Necrobiosis Lipoidica (NL) is a chronic skin condition with no currently approved U.S. Food and Drug Administration (FDA) treatment. It is believed that NL affects 22,000 - 50,000 people in the United States and is more common in individuals with diabetes and women, with an average age of onset between 20 and 60 years. People with NL experience a persistent skin condition that develops into ulcerated lesions in about one-third of cases. Ulceration can cause severe complications, such as life-threatening infections and necrosis.
Processa Pharmaceuticals is conducting a randomized, double blind, placebo-controlled study that will evaluate the efficacy and safety of PCS499 as compared to placebo for the treatment of ulcerations of patients with Necrobiosis Lipoidica (NCT#NCT04800562). This study is currently recruiting in the United States and is expected to enroll a total of 20 patients.
Sian Bigora, Pharm.D., Chief Development Officer, said, 'For patients with NL, the tissue below the skin can become necrotic forming open ulcers which can last from months to years with complications such as infections, amputation, and cancer. Currently there is no FDA approved treatment for uNL or NL, no standard of care, and the treatments that are used are generally inadequate. We are conducting the Phase 2b study to hopefully show that PCS499 can be an option for these patients who currently have little to no options available'
For more information on the clinical study of PCS499, please visit Necrobiosislipoidicastudy.com
PCS499
PCS499, is a deuterated analog of a major metabolite of pentoxifylline (PTX...
To continue reading
Request your trial